Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

 

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Cost containment and managed care in liver transplantationCovered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites : a retrospective cohort study

Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium

Price: €10,00








April-June Volume 65, fasc. 2

Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium

J.B. Wong, F. Nevens.(1) Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA ; (2) Department of Medicine, Division of Hepatology, Catholic University Hospitals, Leuven, Belgium.

Introduction Initial therapy with peginterferon alfa-2b and ribavirin results in a higher sustained virological response but is more expensive than interferon alfa-2b and ribavirin. The objective of the analysis was to examine the costeffectiveness of peginterferon alfa-2b combination therapy versus interferon alfa-2b combination therapy for treatment naïve chronic hepatitis C patients in Belgium. Methods Data from a recent randomised clinical trial (1) comparing these therapies were applied to a previously published computer cohort simulation (2) to project lifelong clinical and economic outcomes. Natural history estimates.....